Medullary thyroid cancer

Also found in: Encyclopedia.

Medullary thyroid cancer (MTC)

A slow-growing tumor associated with MEN.
References in periodicals archive ?
The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer
Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Currently, COMETRIQ (cabozantinib) is approved by the US Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer, concluded the company.
ST), a speciality healthcare company, announced on Thursday the signing of a three-year agreement to support the distribution and commercialisation of COMETRIQ (cabozantinib) for metastatic medullary thyroid cancer (MTC) in the European Union (EU) and potentially other countries.
Extended-release exenatide has been approved with a Risk Evaluation and Mitigation Strategy (REMS), to ensure that the benefits of the drug outweigh the risks of acute pancreatitis and the "potential" risk of medullary thyroid cancer with treatment.
It is contraindicated in people with a personal or family history of medullary thyroid cancer or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.
Calcitonin (CT) [12] is an extremely sensitive marker for both the initial diagnosis and follow-up of patients with medullary thyroid cancer (MTC) (1-5).
Other malignant diseases of the thyroid include medullary thyroid cancer, primary lymphoma, sarcomas and metastases to the thyroid gland.
Medullary thyroid cancer is a malignancy of the parafollicular cells and is often seen in such syndromes as multiple endocrine neoplasia (MEN).